LENZ THERAPEUTICS, INC. Severance Costs
LENZ THERAPEUTICS, INC. (LENZ) reported Severance Costs of -$6.57 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-27.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SeveranceCosts1 · last filed 2024-02-27
- LENZ THERAPEUTICS, INC. severance costs for the quarter ending 2023-12-31 was -$1.67M.
- LENZ THERAPEUTICS, INC. severance costs for the quarter ending 2023-09-30 was -$1.96M.
- LENZ THERAPEUTICS, INC. severance costs for the quarter ending 2023-06-30 was -$2.51M.
- LENZ THERAPEUTICS, INC. severance costs for the quarter ending 2023-03-31 was -$430.00K.
- LENZ THERAPEUTICS, INC. severance costs for fiscal 2023 was -$6.57M.
| Period end | Severance Costs 3 month | Severance Costs 6 month | Severance Costs 9 month | Severance Costs 12 month |
|---|---|---|---|---|
| 2023-12-31 | -$1.67M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$3.62M derived: sum of 2 quarters · filed 2024-02-27 | -$6.13M derived: sum of 3 quarters · filed 2024-02-27 | -$6.57M 10-K · filed 2024-02-27 |
| 2023-09-30 | -$1.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$4.47M derived: sum of 2 quarters · filed 2023-11-13 | -$4.90M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | -$2.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$2.94M 10-Q · filed 2023-08-14 | ||
| 2023-03-31 | -$430.00K 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |